Literature DB >> 2168822

Autoantibodies against neutrophil cytoplasm components in systemic lupus erythematosus and in hydralazine-induced lupus.

L Nässberger1, A G Sjöholm, H Jonsson, G Sturfelt, A Akesson.   

Abstract

Anti-neutrophil cytoplasm antibody (ANCA) has been shown to be no marker of systemic lupus erythematosus (SLE) including lupus nephritis or of progressive systemic sclerosis (PSS). Antibodies against myeloperoxidase (anti-MPO) and elastase, two granulocyte lysosomal enzymes, were found in patients with SLE but not in those with PSS, except for one patient who had anti-MPO. Anti-MPO was present in 21% of patients with SLE, and at low concentrations in about 80% of these cases. Anti-elastase was found in four patients with SLE. In another group of six patients with a SLE-like syndrome induced by anti-hypertensive treatment with the anti-hypertensive hydralazine, anti-MPO antibodies occurred in all six, and anti-elastase antibodies in five. Monitored during a 2-year follow-up period, anti-MPO antibodies were found to persist, whereas anti-elastase antibodies were rapidly eliminated, after withdrawal of the drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2168822      PMCID: PMC1534988          DOI: 10.1111/j.1365-2249.1990.tb05342.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Enzyme immunoassays in diagnostic medicine. Theory and practice.

Authors:  A Voller; D E Bidwell; A Bartlett
Journal:  Bull World Health Organ       Date:  1976       Impact factor: 9.408

Review 2.  Medical intelligence drug therapy.

Authors:  J Koch-Weser
Journal:  N Engl J Med       Date:  1976-08-05       Impact factor: 91.245

3.  Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population.

Authors:  H Jonsson; O Nived; G Sturfelt
Journal:  Medicine (Baltimore)       Date:  1989-05       Impact factor: 1.889

Review 4.  Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors:  H M Perry
Journal:  Am J Med       Date:  1973-01       Impact factor: 4.965

5.  Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.

Authors:  H M Perry; E M Tan; S Carmody; A Sakamoto
Journal:  J Lab Clin Med       Date:  1970-07

6.  Relationships between antibodies to native DNA and glomerulonephritis in systemic lupus erythematosus.

Authors:  F Tron; J F Bach
Journal:  Clin Exp Immunol       Date:  1977-06       Impact factor: 4.330

7.  Hydrallazine in hypertension: is there a safe dose?

Authors:  R F Bing; G I Russell; H Thurston; J D Swales
Journal:  Br Med J       Date:  1980-08-02

8.  Hydrallazine-induced cutaneous vasculitis.

Authors:  R M Bernstein; J Egerton-Vernon; J Webster
Journal:  Br Med J       Date:  1980-01-19

9.  Circulating anti-neutrophil cytoplasm antibodies in patients with rapidly progressive glomerulonephritis and extracapillary proliferation.

Authors:  L Nässberger; A G Sjöholm; P Bygren; H Thysell; M Højer-Madsen; N Rasmussen
Journal:  J Intern Med       Date:  1989-03       Impact factor: 8.989

10.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05
View more
  28 in total

1.  Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features.

Authors:  K Nishiya; H Chikazawa; S Nishimura; N Hisakawa; K Hashimoto
Journal:  Clin Rheumatol       Date:  1997-01       Impact factor: 2.980

Review 2.  Neutrophils in the pathogenesis and manifestations of SLE.

Authors:  Mariana J Kaplan
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

3.  TLR9 Deficiency Leads to Accelerated Renal Disease and Myeloid Lineage Abnormalities in Pristane-Induced Murine Lupus.

Authors:  Lukas Bossaller; Anette Christ; Karin Pelka; Kerstin Nündel; Ping-I Chiang; Catherine Pang; Neha Mishra; Patricia Busto; Ramon G Bonegio; Reinhold Ernst Schmidt; Eicke Latz; Ann Marshak-Rothstein
Journal:  J Immunol       Date:  2016-06-27       Impact factor: 5.422

4.  Combined ANCA-associated vasculitis and lupus syndrome following prolonged use of hydralazine: a timely reminder of an old foe.

Authors:  N Sangala; R W Lee; C Horsfield; D J A Goldsmith
Journal:  Int Urol Nephrol       Date:  2009-08-15       Impact factor: 2.370

Review 5.  The diversity of perinuclear antineutrophil cytoplasmic antibodies (pANCA) antigens.

Authors:  A Wiik; L Stummann; L Kjeldsen; N Borregaard; S Ullman; S Jacobsen; P Halberg
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

6.  Antineutrophil cytoplasmic antibodies in systemic sclerosis.

Authors:  S Kiraz; H Simsek; I Ertenli; M Benekli; A Kadayifci
Journal:  Clin Rheumatol       Date:  1996-09       Impact factor: 2.980

7.  Autoantibodies to native myeloperoxidase in patients with pulmonary hemorrhage and acute renal failure.

Authors:  D E Roberts; C Peebles; J G Curd; E M Tan; R L Rubin
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

Review 8.  B cell-mediated pathogenesis of ANCA-mediated vasculitis.

Authors:  J Charles Jennette; Ronald J Falk
Journal:  Semin Immunopathol       Date:  2014-04-29       Impact factor: 9.623

9.  A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies.

Authors:  J A Savige; B Paspaliaris; R Silvestrini; D Davies; T Nikoloutsopoulos; A Sturgess; J Neil; W Pollock; K Dunster; M Hendle
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

10.  Production of human monoclonal antibodies to myeloperoxidase.

Authors:  M R Ehrenstein; B Leaker; D Isenberg; G Cambridge
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.